SGLT2 inhibitors, an accomplished development in field of medicinal chemistry: An extensive review

Anirudh Manoj, Subham Das, Anu Kunnath Ramachandran, Angel T. Alex, Alex Joseph

Research output: Contribution to journalReview articlepeer-review

Abstract

Diabetes is a chronic progressive metabolic disease caused by insulin deficiency or insulin resistance. In spite of the availability of several antihyperglycaemics, there is a need for the development of safer antidiabetic drugs due to their undesirable effects. Sodium-glucose cotransporter-2 inhibitors are a class of antidiabetics, which hinder the reabsorption of glucose in the kidneys, causing excretion of glucose via urine. Sodium-glucose cotransporter-2 inhibitors are a well-tolerated class with no significant adverse effects and are found to be favorable in certain conditions, which may be rudimentary to cardiovascular and renal diseases. The current advancements in their design and development, their mechanism of action, structure-activity relationship, synthesis and in silico development along with their auxiliary roles have been extensively reviewed.

Original languageEnglish
Pages (from-to)1961-1990
Number of pages30
JournalFuture Medicinal Chemistry
Volume12
Issue number21
DOIs
Publication statusPublished - 11-2020

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Pharmacology
  • Drug Discovery

Fingerprint Dive into the research topics of 'SGLT2 inhibitors, an accomplished development in field of medicinal chemistry: An extensive review'. Together they form a unique fingerprint.

Cite this